Incontinence may be defined as the involuntary loss of bladder or bowel control. In the United States (U.S.), urinary incontinence (UI) afflicts an estimated 50 million people. According to the National Association for Continence (NAFC), approximately 75% to 80% of the UI populations are women, with 9 million to 13 million suffering severe symptoms.
Although UI is an extremely common problem, and has a significant impact on quality of life, the vast majority of those who experience the condition do not undergo treatment, in part due to cost, embarrassment, or fear of risky surgical procedures. There is therefore a very strong demand for less costly, less invasive and more tolerable, discreet, nonsurgical UI therapies.
While current economic conditions and other factors continue to restrain market growth, the market for minimally invasive UI therapy systems is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $190 million in 2010, the U.S. Minimally Invasive Urinary Incontinence Therapy Systems market is expected to increase at a healthy compound annual rate of 2.7%, with sales reaching more than $220 million in 2015. The market is expected to benefit not only from strong demand but from highly positive demographic trends, including a large, growing UI population and limited options for truly effective therapeutic alternatives.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include injectable urethral bulking agents; urethral sling systems; implantable sacral nerve neurostimulators; nonsurgical office-based neuromodulation/percutaneous tibial nerve stimulation; and other nonsurgical treatments.